Peripheral arterial disease: a literature review

被引:75
作者
Abdulhannan, P. [1 ]
Russell, D. A. [1 ]
Homer-Vanniasinkam, S. [1 ]
机构
[1] Leeds Gen Infirm, Leeds Vasc Inst, Leeds LS1 3EX, W Yorkshire, England
关键词
peripheral arterial disease; atherosclerosis; revascularization; bypass surgery; atherectomy; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; SUPERFICIAL FEMORAL-ARTERY; NITINOL STENT IMPLANTATION; BALLOON ANGIOPLASTY; LOWER-EXTREMITY; RISK-FACTORS; INTERMITTENT CLAUDICATION; SUPERVISED EXERCISE; VASCULAR-DISEASE; ELUTING STENTS;
D O I
10.1093/bmb/lds027
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Peripheral arterial disease (PAD) is a common vascular condition that affects both quality of life and life expectancy with an increased risk of cardiovascular events. A literature search was carried out of Pub-Med, MEDLINE, the Cochrane Library and Google Scholar from the establishment of these databases up to February 2012. The search was performed by using the keywords operipheral arterial disease' and one of the following words: omanagement', oinvestigations', orisk factors', oepidemiology', orevascularization', ocryoplasty', oatherectomy' and ogene therapy'. Studies were limited to those published in English language. Aggressive risk factors modification is needed to reduce cardiovascular-related mortality in PAD patients. Choice of endovascular or surgical intervention remains controversial in an ever-evolving field. There is a rapid expansion of endovascular technologies aiming to improve the effectiveness of this modality. The advances in the fields of gene therapy and therapeutic angiogenesis mean these are potential future treatments. Tissue engineering is a developing area and aims to produce grafts with similar patency and infection profiles to those of autologous material. Further elucidation of the pathophysiology of atherosclerosis is required to provide new targets for pharmacotherapy.
引用
收藏
页码:21 / 39
页数:19
相关论文
共 69 条
[1]
Anand S, 2007, NEW ENGL J MED, V357, P217
[2]
[Anonymous], NICE CLINICAL GUIDEL
[3]
[Anonymous], COMPANION SPECIALIST
[4]
[Anonymous], NICE technology appraisal guidance TA597. Dapagliflozin with insulin for treating type 1 diabetes
[5]
[Anonymous], NICE INTERVENTIONAL
[6]
Nephrotoxic effects in high-risk patients undergoing angiography. [J].
Aspelin, P ;
Aubry, P ;
Fransson, S ;
Strasser, R ;
Willenbrock, R ;
Berg, KJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :491-499
[7]
Bartholomew John R, 2006, Cleve Clin J Med, V73 Suppl 4, pS8
[8]
Definitions, Epidemiology, Clinical Presentation and Prognosis [J].
Becker, F. ;
Robert-Ebadi, H. ;
Ricco, J. -B. ;
Setacci, C. ;
Cao, P. ;
de Donato, G. ;
Eckstein, H. H. ;
de Rango, P. ;
Diehm, N. ;
Schmidli, J. ;
Teraa, M. ;
Mall, F. L. ;
Dick, F. ;
Davies, A. H. ;
Lepantalo, M. ;
Apelqvist, J. .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2011, 42 :S4-S12
[9]
Berridge D, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858, DOI 10.1002/14651858]
[10]
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717